C tier · mixed
Flibanserin is FDA-approved on the basis of statistically significant but small randomised effects — roughly half an additional satisfying sexual event per month in independent meta-analysis — set against a boxed warning and markedly elevated rates of dizziness, somnolence and discontinuation.
flibanserin
Flibanserin is approved for acquired, generalised hypoactive sexual desire disorder in premenopausal women, and its label carries a boxed warning for hypotension and syncope. Independent meta-analysis has found the efficacy effect sizes small and the adverse event rates substantially elevated relative to placebo, which is the core of the ongoing debate about its clinical value.
the explanation
Flibanserin is a daily pill for low sexual desire in women that acts on brain serotonin and dopamine systems rather than on blood flow. Trials showed a real but small benefit, roughly half an extra satisfying sexual event per month, alongside a boxed warning about fainting and dangerously low blood pressure with alcohol.
regulatory status
FDA-approved with BOXED WARNING
Approved for acquired, generalised hypoactive sexual desire disorder in women under 65 whose low desire causes marked distress or interpersonal difficulty, excluding cases attributable to medical or psychiatric conditions, relationship problems or medication effects. The label carries a boxed warning for hypotension and syncope in certain settings. Approval was contested and was granted after prior rejections.
how it works · proposed mechanism
Flibanserin acts centrally on serotonergic and dopaminergic circuits implicated in the regulation of sexual desire.
5-HT1A agonism
Agonism at postsynaptic 5-HT1A receptors in prefrontal cortex is proposed to reduce serotonergic inhibitory tone over sexual desire circuitry. This is the opposite direction from SSRIs, which commonly suppress desire.
5-HT2A antagonism and dopamine effects
Antagonism at 5-HT2A receptors, together with dopamine D4 activity, is hypothesised to raise prefrontal dopamine and noradrenaline relative to serotonin. The net proposed effect is a shift in excitatory-inhibitory balance rather than a peripheral vascular action.
CYP3A4-dependent exposure and hypotension
Flibanserin is extensively metabolised by CYP3A4, so inhibitors and hepatic impairment sharply raise exposure. Because its adverse effect profile is dominated by hypotension and syncope, these become contraindications rather than cautions.
what’s reported
evidence shape
4 sourcesThe composition of the cited literature by study type. This describes the shape of the evidence, not its quality — and it does not by itself set the grade.
⚠ the catch
Flibanserin is approved specifically for acquired, generalised hypoactive sexual desire disorder in premenopausal women with marked distress, and its evidence explicitly does not cover low desire arising from relationship problems, other medications, or medical and psychiatric conditions — nor does it support use as a general libido or performance enhancer. The boxed warning on hypotension and syncope with alcohol, CYP3A4 inhibitors and hepatic impairment is the reason this drug is dispensed under supervision rather than bought casually.
key published findings
- Regulatory (boxed warning): 'WARNING: HYPOTENSION and SYNCOPE IN CERTAIN SETTINGS' — alcohol use increases the risk of severe hypotension and syncope, and use with moderate or strong CYP3A4 inhibitors or in hepatic impairment is contraindicated.
- Human trial (meta-analysis, 8 studies including 3 unpublished, 5,914 women): Jaspers and colleagues found 0.49 additional satisfying sexual events per month versus placebo (95% CI 0.32-0.67), an eDiary sexual desire difference of 1.63 (95% CI 0.45-2.82) and an FSFI desire domain difference of 0.27 (95% CI 0.17-0.38).
- Human trial (same meta-analysis, harms): risk ratios versus placebo were 4.00 for dizziness (95% CI 2.56-6.27), 3.97 for somnolence (95% CI 3.01-5.24), 2.35 for nausea (95% CI 1.85-2.98), 1.64 for fatigue (95% CI 1.27-2.13), and 2.19 for study discontinuation due to adverse events (95% CI 1.50-3.20).
- Regulatory (label, premenopausal Studies 1-3): satisfying sexual events increased by 0.9-1.0 on flibanserin versus 0.5-0.8 on placebo; FSFI Desire improved by 0.3-0.4 points over placebo; FSDS-R Question 13 improved by -0.3 to -0.4 points.
- Regulatory (label, postmenopausal Study 6): satisfying sexual events showed a 0.4-point advantage, FSFI Desire a 0.3-point improvement, and FSDS-R Question 13 a -0.2 point reduction — smaller still than the premenopausal result.
limitations of the evidence
- The absolute benefit is roughly half an additional satisfying sexual event per month, an effect whose clinical meaningfulness to patients is genuinely disputed rather than merely debated at the margins.
- Blinding is likely imperfect given the fourfold excess of dizziness and somnolence, which could inflate self-reported desire and event outcomes.
- Three of the eight studies in the definitive meta-analysis were unpublished at the time of pooling, and the published literature alone gave an incomplete picture of the evidence base.
documented safety signals
- BOXED WARNING: hypotension and syncope in certain settings — specifically with alcohol use, with moderate or strong CYP3A4 inhibitors, and in hepatic impairment.
- CONTRAINDICATED with moderate or strong CYP3A4 inhibitors and in patients with any degree of hepatic impairment.
- Alcohol interaction is the central safety issue and was the subject of sustained regulatory attention, with the label evolving over multiple revisions.
- Dizziness occurred at four times the placebo rate (RR 4.00) and somnolence at nearly four times (RR 3.97) in pooled randomised data.
- Discontinuation due to adverse events was more than twice as likely as on placebo (RR 2.19).
- Nausea and fatigue were significantly elevated (RR 2.35 and 1.64 respectively).
- Additive central nervous system depression with other CNS depressants including hypnotics, benzodiazepines and opioids.
- Somnolence and sedation raise concerns for activities requiring alertness, with the label addressing timing relative to activity.
- Effectiveness and safety in women 65 and older have not been established, and the approved population is explicitly restricted below that age.
- Because efficacy is modest and adverse effects common, the benefit-risk balance is sensitive to correct patient selection — which unsupervised purchase cannot provide.
identity
| full name | Flibanserin |
| category | Sexual Health |
| modality | small molecule |
| formula | C20H21F3N4O |
| molar mass | 390.4 g/mol |
| cas | 167933-07-5 |
| half-life | ~11 h (terminal) |
laboratory handling
| storage | Marketed film-coated tablets are stored at controlled room temperature per the approved label. |
| solubility | Flibanserin is a weak base with limited aqueous solubility that is pH-dependent, being more soluble under acidic conditions; it is formulated as a solid oral tablet. |
| co-studied with | Documented hazards rather than a regimen: alcohol is the subject of the boxed warning; moderate and strong CYP3A4 inhibitors are contraindicated because they sharply raise exposure and hypotension risk; hepatic impairment is contraindicated for the same reason; and additive sedation occurs with other CNS depressants. These are the specific combinations the boxed warning exists to prevent. |
Handling information describes laboratory practice for a research reagent. It is not a preparation guide for use in humans.
the receipts
4 citedUS FDA Drugs@FDA · 2025 · official
DailyMed / US FDA · 2025 · official
Progrès en Urologie · 2016 · review
JAMA Internal Medicine · 2016 · randomized
others in Sexual Health